Zhenggang Ren, Tingbo Liang, Shanzhi Gu, Hongfeng Gou, Chuang Peng, Yueyin Pan et al. First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study. // Advances in Therapy. – 2026. – DOI: 10.1007/s12325-026-03578-4. – URL: https://doi.org/10.1007/s12325-026-03578-4
Zhenggang Ren, Tingbo Liang, Shanzhi Gu, Hongfeng Gou, Chuang Peng, Yueyin Pan, Tianqiang Song, Haichuan Su, Ke Cao, Houjie Liang, Jieer Ying, Zhimin Geng, Wenchang Yu, Haitao Zhao, Yuxian Bai, Chunyi Hao, Yimin Mao, Wei Li, Lu Wang, Dongliang Li, Wenmiao Wang, Nan Li, Usha Malhotra, & Shukui Qin (2026). First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03578-4
Zhenggang Ren, et al. “First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.” Advances in Therapy, 2026. doi:10.1007/s12325-026-03578-4.
@article{Ren2026,
title = {First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study},
author = {Ren, Zhenggang and Liang, Tingbo and Gu, Shanzhi and Gou, Hongfeng and Peng, Chuang and Pan, Yueyin and Song, Tianqiang and Su, Haichuan and Cao, Ke and Liang, Houjie and Ying, Jieer and Geng, Zhimin and Yu, Wenchang and Zhao, Haitao and Bai, Yuxian and Hao, Chunyi and Mao, Yimin and Li, Wei and Wang, Lu and Li, Dongliang and Wang, Wenmiao and Li, Nan and Malhotra, Usha and Qin, Shukui},
journal = {Advances in Therapy},
year = {2026},
doi = {10.1007/s12325-026-03578-4},
url = {https://doi.org/10.1007/s12325-026-03578-4}
}